- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02832349
Impact of Educational Actions on the Quality Of Life of Epileptic Patients (EQOLE)
Study Overview
Detailed Description
Introduction:
Epilepsy is a common neurological disease with an estimated annual incidence of 43 cases per 100,000 population in developed countries (McHugh et al;. 2008). It is a chronic disease that can be disabling for the patient and his family. The management of patients with epilepsy must consider the quality of life, improving the quality of life is precisely one of the main objectives of therapeutic education (WHO1996).
Background and rational of the study:
The Epilepsy Patient Education (EPE) is very important for the comprehension of the disease and its management. By offering a better knowledge about the disease, helping the patients to learn how to manage crises and treatments, and especially, how to develop strategies to adapt to specific life situations, the EPE allows patients and caregivers to acquire together some autonomy and some skills that will help them live better with the disease.
Objectives:
The primary objective of this study is to evaluate the impact of a program of educational activities (EA) on the quality of life of epileptic patients measured by the validated scale Quality Of Life in Epilepsy -31 (QOLIE-31).
The secondary objectives are to study the evolution of knowledge of patients, to compare the frequency of crises and seeking care before and after the program, and to study the role of certain characteristics of the patient and his disease on response to the program.
Methodology:
This is a single-center, randomized, open, comparative, and longitudinal study with a duration of approximately 30 months, including 80 patients.
Patients eligible to the study will be screened among epileptic patients followed-up by the neurologists specialized in epilepsy at the University Hospital of Caen. Patients should be major with an epileptic disease diagnosed for at least 6 months without other disabling chronic condition.
Each pre-included patient will receive written information about the study. During the usual visit to the neurologist, a detailed letter of information about the study will be given to the patient and the various criteria will be evaluated. After randomization, patients will be divided into 2 groups: the first (EA group) will be included in the program of educational activities, while the second, control group (C group) will have a "standard" follow-up. An individual educational session and 3 group educational sessions (5-6 patients per group) built around the epileptic disease, its treatment and daily life, will constitute the program of EA group.
Six months after inclusion, during the usual visit, the various criteria will be reassessed with the patient, to evaluate the degree of benefice of EA.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Caen, France
- Caen University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Major epileptic patient
- Epilepsy diagnosed for at least 6 months before inclusion
Exclusion Criteria:
- Patient with mental disabilities (patient in an institution or with communication disorders, speech and verbal comprehension)
- Patients with disabling chronic condition other than epilepsy
- Patient consulting for the first time
- Patient whose diagnosis of epilepsy date of less than 6 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: EA group (Educational Actions)
Epileptic patients participating to the educational actions program
|
Individual educational session and 3 group educational sessions (5-6 patients per group) built around the epileptic disease, its treatment and daily life, will constitute the program of EA group.
|
No Intervention: Control group
Epileptic patients with standard follow-up
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Score difference at the scale Quality Of Life in Epilepsy -31 (QOLIE-31 )
Time Frame: Six months after enrollment
|
Six months after enrollment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sophie FONTAINE, Mme, University Hospital, Caen
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 15-206
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
Great Ormond Street Hospital for Children NHS Foundation...Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, FocalUnited Kingdom
-
University of British ColumbiaTerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence EpilepsyCanada
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Neuroelectrics CorporationRecruitingEpilepsy | Seizures | Refractory Epilepsy | Epilepsy, Tonic-Clonic | Epilepsy in Children | Seizures, Focal | Focal SeizureSpain, United States, France, Belgium
-
Oslo University HospitalCompletedEpilepsy | Generalized Epilepsy | Focal EpilepsyNorway
-
UCB Pharma SACompletedEpilepsy, Tonic-clonicPoland, Sweden, Hungary, Czechia
-
UCB PharmaCompletedEpilepsy, Tonic-clonic
-
University Hospital, LilleUnknownFocal Epilepsy | Epilepsy IntractableFrance
-
Xuanwu Hospital, BeijingPeking University; Beijing Tiantan Hospital; Qilu Hospital of Shandong University and other collaboratorsNot yet recruitingEpilepsy, Drug ResistantChina
Clinical Trials on Educational Actions
-
AG ClinicHospital Universitario La PazCompletedChronic Pain
-
Rennes University HospitalInstitut National de Recherche en Informatique et en AutomatiqueWithdrawnWeakness of the Lower LimbsFrance
-
Tampere University HospitalTerminatedPancreatic Cancer | Surgery--Complications | Pancreatic Fistula | Delayed Gastric Emptying | Pancreatic HemorrhageFinland
-
University of Texas at AustinTerminated
-
Seattle Children's HospitalNational Institute of Mental Health (NIMH)Completed
-
Universidad de AntioquiaRecruitingPatient EmpowermentColombia
-
Oregon Research InstituteCompletedCannabis Use Disorder, Mild | Cannabis Use Disorder, ModerateUnited States
-
Jimma UniversityUnknown
-
Hospital of South West JutlandAarhus University Hospital; Hvidovre University Hospital; Herlev HospitalEnrolling by invitationLiver Cirrhosis | Quality of Life | Nurse-Patient Relations | End of Life CareDenmark
-
Centre hospitalier de l'Université de Montréal...Eiffel MedtechNot yet recruitingKnee Osteoarthritis | Clinical Outcomes | Knee Instability | 3D Knee Kinematics | Precision of Surgical ActionsCanada